Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Lexicon Pharmaceuticals reports strong Q4 performance and eyes growth

Lexicon Pharmaceuticals showcased promising drug candidates and financial stability in Q4 2022.
While facing challenges in revenue generation and expense management, the company is strategically positioned for growth.
Opportunities lie in commercial launches, Phase 3 advancements, and potential partnerships to drive future success.
Overall, Lexicon's focus on maximizing asset value and advancing key drugs positions them for long-term success in the pharmaceutical market.

Lexicon Pharmaceuticals reports robust Q1 performance and eyes market expansion

Lexicon Pharmaceuticals showcased strong financials, promising drug candidates, and strategic confidence in market success.
Challenges lie in market penetration strategies, FDA feedback, and successful commercialization amidst competition.
Opportunities abound with upcoming sotagliflozin launch, advancing LX9211, and leveraging unique data for growth.

Lexicon Pharmaceuticals reports strong Q2 earnings and advances key treatments

Lexicon Pharmaceuticals demonstrated financial stability and strategic progress in Q2 2023, supported by strong cash reserves and key regulatory milestones.
The company's focus on patient-centric initiatives and upcoming product launches positions it for sustained growth and market success.
Challenges in market penetration and revenue realization require targeted strategies, while opportunities in market expansion and pipeline development offer avenues for growth.
Overall, Lexicon Pharmaceuticals shows promise with a solid foundation for future success, driven by innovation and market-focused strategies.

Lexicon Pharmaceuticals reports Q3 loss, highlights INPEFA progress and global expansion

Lexicon Pharmaceuticals faces challenges in market access and inventory trends while capitalizing on opportunities through geographic expansion and potential partnerships. The company's financial performance in Q3 2023 showed increased expenses but progress in prescription demand for INPEFA.

Lexicon Pharmaceuticals reports strong Q1 performance and growth opportunities

Lexicon Pharmaceuticals showcased strong performance and progress in Q1 2024, with a focus on product launches and market access.
Despite challenges in achieving full access and addressing specific patient needs, the company remains optimistic about future growth opportunities.
Positive customer feedback, ongoing pipeline advancements, and strategic market considerations position Lexicon well for future success and sales acceleration.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

THE WOODLANDS, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon's executive vice president, corporate and administrative affairs and chief financial officer, will participate in a live fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 a.m. ET.

Lexicon Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference

Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.

Implied Volatility Surging for Lexicon Pharmaceuticals (LXRX) Stock Options

Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q4 2020 Results - Earnings Call Transcript

Conference Call and Webcast at 5:00 pm Eastern Time Conference Call and Webcast at 5:00 pm Eastern Time

Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Clinical Update

On Wednesday, March 10, Lexicon Pharmaceuticals (NASDAQ:LXRX) will release its latest earnings report. Benzinga's outlook for Lexicon Pharmaceuticals is included in the following report.

Earnings Preview: Lexicon Pharmaceuticals

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Lexicon Pharmaceuticals (LXRX) Report Negative Q4 Earnings? What You Should Know

Sotagliflozin was rejected by the FDA in 2019 citing diabetic ketoacidosis in type 1 diabetes patients. This time, the company has a new approach and some strong CV benefits data that may change the FDA's viewpoint.

Lexicon's Sotagliflozin: New Approach To Safety May Make Approval Easier

ADMA Biologics

Atea Pharmaceuticals

BioNTech SE

Moderna

Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.

4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Your portfolio could benefit from its group of soon-to-be-commercialized drugs.

Should You Buy Lexicon Pharmaceuticals Stock?

Biogen

3D Systems

Duke Energy

Ford Motor Company

Akebia Therapeutics

Harley-Davidson

Vail Resorts

PulteGroup

Sorrento Therapeutics Inc

With the trading day practically over, the broad markets were sliding into the weekend.

Biogen, 3D Systems, Duke Energy, Ford and More of Friday Afternoon's Analyst Calls

Corcept Therapeutics

CRISPR Therapeutics

Fate Therapeutics

Jounce Therapeutics

Time will always be on the investor's side.

Got $5,000 and 5 Years to Wait? Buy These 5 Hot Biotech Stocks Now

Amphastar Pharma

Evoqua Water Technologies

Barings BDC Inc

Biohaven Pharmaceutical Hld

Colfax

Crh Medical

Global Blood Therapeutics

Hannon Armstrong Sustainable Infrastructure Capital

Houghton Mifflin Harcourt

MannKind

Nektar Therapeutics

Nano-X Imaging

ObsEva

Personalis Inc

PIMCO Corporate & Income Opportunity Fund

Construction Partners

Surgery Partners

SP Plus

Takeda Pharmaceutical

Cohen & Steers Infrastructure Fund Inc

Xerium Technologies

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Final Update For My 20/20 Vision For 2020 Dividend Paying Stocks

The stock price of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) increased by 78.21% this past week. This is why it happened.

LXRX Stock Price Increased By 78.21% This Past Week: Why It Happened

Aldeyra Therapeutics

NuCana

Find out what led to the biotech industry's biggest gains.

3 Biotech Stocks That Jumped Last Week

A downgrade from an analyst might have something to do with it.

Why Lexicon Pharmaceuticals Stock Is Down Today

Lexicon (LXRX) announces that data from two late-stage studies on its type II diabetes candidate, sotagliflozin, can support a regulatory approval application.

Lexicon (LXRX) Soars on FDA Permission for Sotagliflozin NDA

The FDA delivered a powerful shot of good news to the company.

Why Lexicon Pharmaceuticals Stock Doubled and Then Some on Thursday

Lexicon Pharmaceuticals (NASDAQ: LXRX) shares are trading sharply higher after the company announced it received FDA regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application submission. Lexicon is a biopharmaceutical company developing medicines that transform patients' lives.

Why Lexicon Pharma's Stock Is Surging Higher Today

Lexicon Pharmaceuticals (LXRX) stock is on the rise Thursday after announcing an update from the FDA for its drug sotagliflozin. The post LXRX Stock Alert: Why Lexicon Pharmaceuticals Is Up 100%+ Today appeared first on InvestorPlace.

LXRX Stock Alert: Why Lexicon Pharmaceuticals Is Up 100%+ Today

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares jumped on Thursday morning after the company announced that it received regulatory feedback from the U.S.

Is Lexicon Pharma a Stock to Buy After 90% Runup and FDA Nod?

THE WOODLANDS, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application (NDA) submission for an indication to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure.

Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure

Lexicon (LXRX) initiates dosing in a mid-stage study on LX9211 for the treatment of post-herpetic neuralgia.

Lexicon (LXRX) Starts Dosing in Post-Herpetic Neuralgia Study

THE WOODLANDS, Texas, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of post-herpetic neuralgia. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1).

Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia

Lexicon Pharmaceuticals (LXRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Lexicon Pharmaceuticals (LXRX)

Weightwatchers International Inc.

Lexicon Pharma sold LXRX stock to Weight Watchers' turn-around billionaire. Lexicon sold 15% of LXRX stock to Ray Debbane's private equity company which turned Weight Watchers around.

Lexicon Pharma Sold LXRX Stock to Weight Watchers' Turn-Around Billionaire

News for Lexicon Pharmaceuticals Stock (LXRX)